Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome

DOI Full Paper Access

69

Citations

33

References

2022

Year

Jing He, Jiali Chen, Miao Miao, Ruijun Zhang, Gong Cheng, Yifan Wang, Ruiling Feng, Bo Huang, Huijie Luan, Yuan Jia,

JAMA Network Open

Abstract

ClinicalTrials.gov Identifier: NCT02464319.

References

	Year	Citations
World Medical Association Declaration of Helsinki JAMA Biomedical EthicEthical PrinciplesResearch EthicsEthical PracticeMedical Tourism	2013	27.3K
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease John Koreth, Ken‐ichi Matsuoka, Haesook T. Kim, New England Journal of Medicine	2011	1.1K
Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells Yohei Iwata, Takashi Matsushita, Mayuka Horikawa, Blood	2010	1.1K
EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome Raphaèle Séror, Philippe Ravaud, Simon Bowman, Annals of the Rheumatic Diseases Rheumatoid DisorderRheumatologyAutoimmune DiseaseSjögren’s SyndromeMedicine	2009	910
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis David Saadoun, Michèlle Rosenzwajg, Florence Joly, New England Journal of Medicine	2011	728
Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody Responses upon Antigen Reexposure Jing He, Louis M. Tsai, Yew Ann Leong, Immunity InflammationAutoimmune DiseaseT-regulatory CellImmunologyAntigen Processing	2013	641
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus Jing He, Xia Zhang, Yunbo Wei, Nature Medicine InflammationAllergySystemic Lupus ErythematosusAutoimmune DiseaseLupus	2016	545
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome Raphaèle Séror, Philippe Ravaud, Xavier Mariette, Annals of the Rheumatic Diseases	2011	521
Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial Agnès Hartemann, G. Bensimon, Christine Payan, The Lancet Diabetes & Endocrinology InflammationMetabolic SyndromeType 1Phase 1/2Diabetes Management	2013	414
Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo Joseph N. Blattman, Jason M. Grayson, E. John Wherry, Nature Medicine InflammationAllergyAutoimmune DiseaseAntiviral T-cell ResponsesTherapeutic Use	2003	384

Page 1